Ubs Group Ag Vanda Pharmaceuticals Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Ubs Group Ag holds 63,800 shares of VNDA stock, worth $324,742. This represents 0.0% of its overall portfolio holdings.

Number of Shares

63,800

Previous 78,410 18.63%

Holding current value

$324,742

Previous $443,000 32.51%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.61 - $6.34 $39,051 - $53,706	8,471 Added 10.8%	86,881 $407,000
Q2 2024 Aug 13, 2024	BUY	$3.91 - $6.5 $46,966 - $78,078	12,012 Added 18.09%	78,410 $443,000
Q1 2024 May 13, 2024	SELL	$3.47 - $4.61 $31,969 - $42,471	-9,213 Reduced 12.18%	66,398 $272,000
Q4 2023 Feb 09, 2024	SELL	$3.38 - $4.58 $56,023 - $75,913	-16,575 Reduced 17.98%	75,611 $319,000
Q3 2023 Nov 09, 2023	SELL	$4.28 - $6.57 $169,141 - $259,639	-39,519 Reduced 30.01%	92,186 $398,000
Q2 2023 Aug 11, 2023	SELL	$5.9 - $6.95 $13,015 - $15,331	-2,206 Reduced 1.65%	131,705 $867,000
Q1 2023 May 12, 2023	SELL	$6.18 - $7.99 $30,819 - $39,846	-4,987 Reduced 3.59%	133,911 $909,000
Q4 2022 Feb 08, 2023	BUY	$6.87 - $10.96 $631,318 - $1.01 Million	91,895 Added 195.51%	138,898 $1.03 Million
Q3 2022 Nov 10, 2022	SELL	$9.44 - $11.76 $101,385 - $126,302	-10,740 Reduced 18.6%	47,003 $464,000
Q2 2022 Aug 10, 2022	SELL	$9.31 - $11.84 $695,857 - $884,957	-74,743 Reduced 56.42%	57,743 $630,000
Q1 2022 May 16, 2022	BUY	$10.84 - $16.55 $840,945 - $1.28 Million	77,578 Added 141.29%	132,486 $1.5 Million
Q4 2021 Feb 14, 2022	BUY	$15.69 - $21.14 $82,905 - $111,703	5,284 Added 10.65%	54,908 $861,000
Q3 2021 Nov 15, 2021	BUY	$15.35 - $21.27 $720,268 - $998,052	46,923 Added 1737.25%	49,624 $850,000
Q2 2021 Aug 13, 2021	SELL	$15.71 - $21.51 $1.12 Million - $1.53 Million	-71,063 Reduced 96.34%	2,701 $58,000
Q1 2021 May 12, 2021	BUY	$13.42 - $20.28 $124,457 - $188,076	9,274 Added 14.38%	73,764 $1.11 Million
Q4 2020 Feb 11, 2021	BUY	$9.77 - $13.81 $531,282 - $750,973	54,379 Added 537.82%	64,490 $847,000
Q3 2020 Nov 12, 2020	SELL	$9.32 - $12.02 $146,771 - $189,290	-15,748 Reduced 60.9%	10,111 $98,000
Q2 2020 Jul 31, 2020	BUY	$9.66 - $12.02 $225,116 - $280,114	23,304 Added 912.09%	25,859 $296,000
Q1 2020 May 01, 2020	SELL	$7.5 - $16.8 $544,680 - $1.22 Million	-72,624 Reduced 96.6%	2,555 $26,000
Q4 2019 Feb 14, 2020	SELL	$12.38 - $17.47 $52,107 - $73,531	-4,209 Reduced 5.3%	75,179 $1.23 Million
Q3 2019 Nov 14, 2019	BUY	$12.27 - $15.79 $896,274 - $1.15 Million	73,046 Added 1151.78%	79,388 $1.05 Million
Q2 2019 Aug 14, 2019	SELL	$13.37 - $18.85 $8,021 - $11,310	-600 Reduced 8.64%	6,342 $90,000
Q1 2019 May 14, 2019	SELL	$17.59 - $31.05 $2.88 Million - $5.08 Million	-163,504 Reduced 95.93%	6,942 $127,000
Q4 2018 Feb 14, 2019	BUY	$18.97 - $31.47 $2.75 Million - $4.56 Million	144,907 Added 567.39%	170,446 $4.45 Million
Q3 2018 Nov 14, 2018	BUY	$18.25 - $23.0 $282,145 - $355,580	15,460 Added 153.39%	25,539 $586,000
Q2 2018 Aug 14, 2018	SELL	$13.95 - $19.15 $1.04 Million - $1.43 Million	-74,660 Reduced 88.11%	10,079 $192,000
Q1 2018 May 15, 2018	BUY	$14.05 - $20.2 $314,467 - $452,116	22,382 Added 35.89%	84,739 $1.43 Million
Q4 2017 Feb 14, 2018	SELL	$12.85 - $18.1 $857,711 - $1.21 Million	-66,748 Reduced 51.7%	62,357 $947,000
Q3 2017 Nov 14, 2017	BUY	$15.4 - $18.85 $1.77 Million - $2.16 Million	114,667 Added 794.2%	129,105 $2.31 Million
Q2 2017 Aug 14, 2017	BUY	N/A	2,618 Added 22.15%	14,438 $235,000
Q1 2017 Nov 14, 2017	BUY	N/A	11,820	11,820 $165,000

Others Institutions Holding VNDA

# of Institutions

161

Shares Held

45.2M

Call Options Held

165K

Put Options Held

33.6K

View Full List

About Vanda Pharmaceuticals Inc.

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $288M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

More about VNDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account